The ASH 2024 conference brought together industry leaders to lay out their vision for the future of blood cancer treatment. During a panel discussion, representatives from GlaxoSmithKline, AstraZeneca, Regeneron, and Johnson & Johnson emphasized the importance of aiming for a cure in the treatment of blood cancers. With advancements in therapies like CAR-T therapy, bispecifics, and antibody-drug conjugates, developers are now shifting their focus towards treating patients to achieve a cure rather than managing the disease.
Regeneron presented promising data on Orspono, a bispecific antibody that shows potential in treating newly diagnosed patients with follicular lymphoma. J&J highlighted the benefits of Darzalex in reducing the risk of smoldering myeloma progression. AstraZeneca discussed the development of cancer drug cocktails for defined durations, appealing to younger patients who prefer shorter treatment regimens. Additionally, GSK showcased the potential of Blenrep, an antibody-drug conjugate for multiple myeloma.
Another highlight of the conference was a study on bone marrow transplants for acute myeloid leukemia (AML) patients. While transplants can be transformative for AML patients, the research revealed that patients from disadvantaged communities face barriers in accessing this life-saving treatment. Socioeconomic factors play a significant role in determining who receives a transplant, highlighting the need for better screening and support strategies for these patients.
In a study of 9/11 first responders, researchers uncovered a higher risk of blood cancer linked to toxic dust exposure from the World Trade Center attack. Clonal hematopoiesis mutations were identified as a potential target for treating blood cancers, with IL1RAP emerging as a key receptor in this process. Targeting IL1RAP could help prevent or delay the development of certain blood cancers.
However, not all news from the conference was positive. Pfizer’s sudden withdrawal of the sickle cell drug Oxbryta drew criticism from experts for being “tone deaf.” The drug, initially hailed as a potential game-changer, was found to increase risks of pain crises and fatal events. Experts highlighted systemic flaws in treating sickle cell disease and emphasized the importance of prioritizing patient safety over profits in drug development.
Overall, the ASH 2024 conference provided valuable insights into the future of blood cancer treatment, highlighting the ongoing efforts to improve outcomes for patients through innovative therapies and targeted interventions.
